AKV9 Targets Aggregation, Showing Promise in Both ALS and AD | https://lnkd.in/gkA6Vvvw AKV9, a small molecule discovered in the Silverman lab and advanced by Akava Therapeutics, inhibits protein aggregation via an intracellular, lysosome-dependent mechanism. Originally developed for ALS, AKV9 also shows promise in Alzheimer’s disease by blocking Aβ oligomerization. With oral bioavailability, in vivo efficacy, and low toxicity, AKV9 represents a structurally simple, mechanistically intriguing candidate for multiple neurodegenerative diseases. Read it on Drug Hunter: https://lnkd.in/gkA6Vvvw
Definitely a small molecule!
I am sure that the chemist had a strong urge to alkylate the methylene, but somehow had to control.🙂 Has a good MPO score. Good decision to test the compound in the first place. I would consider this a starting material normally.
Honorary Professor at the University of Edinburgh and owner of TW2Informatics Consulting
2moLot of interesting links over the last decade including WO2023056307 from Silverman https://pubchem.ncbi.nlm.nih.gov/compound/70697510